Aspirin's anti-inflammatory action is protective against another aggressive cancer: cholangiocarcinoma. Furthermore, it is beneficial regardless of daily use or dose.
Researchers revealed a pathway in cell culture and mice by which salicylic acid decreases inflammation and by which salicylic acid and diflunisal decrease cancerous growth.
Greatest survival benefit observed for those taking the drug before their cancer diagnosis.
A low-dose of aspirin could increase survival by up to 20% and help stop metastasis for patients receiving cancer treatment.
USPSTF Releases Updated Recommendations for Aspirin Use to Prevent Cardiovascular Disease and Colorectal CancerApril 18, 2016
The US Preventive Services Task Force (USPSTF) updated its recommendations on low-dose aspirin use for the primary prevention of CVD and the use of aspirin and NSAIDs for prevention of CRC.
Regular, low doses of aspirin for a minimum of 6 years correlated with a small, yet significant reduction in overall cancer risk, due primarily to reductions in risks for colorectal cancer and gastrointestinal cancer.
The anti-cancer effect of low-dose aspirin was seen most strongly with colon and gastrointestinal tumors.
The risk of lethal prostate cancer, but not of overall, high-grade, or advanced cancers, was reduced with regular aspirin use.
Aspirin improves survival in patients with tumors situated throughout the gastrointestinal (GI) tract, according to results from a large study. This is the first time that survival data from patients with tumors in different GI locations have been analyzed at the same time.
A regular regimen of aspirin can reduce additional cancer risk for obese individuals, according to study data.
Regular aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may lower the long-term risk of colorectal cancer (CRC), new study data suggests.
Taking aspirin regularly can negate the increased the risk for developing colorectal cancer in patients with Lynch syndrome.
Aspirin exposure after a colorectal cancer diagnosis was independently associated with improved colorectal cancer-specific survival.
Post-diagnostic aspirin use is not associated with a decreased risk of prostate cancer outcomes, according to study data.
Taking aspirin regularly may help prevent gastrointestinal cancers, a new study suggests, with the greater benefit seen when taking it over many years.
More than 10% of patients are inappropriately taking aspirin for primary prevention of cardiovascular disease.
A recent meta-analysis demonstrated an association between aspirin and a reduced risk of prostate cancer.
Even a small daily dose of aspirin may help lower mortality among men with nonmetastatic prostate cancer, according to research.
Aspirin and other other NSAIDs were associated with a decreased risk for developing an aggressive form of prostate cancer.
Recurrence of hormone-related breast cancer was reduced by 50% in overweight and obese women who regularly used aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), according to newly published data.
Daily aspirin appears beneficial for men and women between ages 50 and 65 in the general population.
In a recent study, researchers found that by taking a daily aspirin, the incidence of gastrointestinal cancers is reduced, as well as a reduction in cancer-specific mortality.
Guidelines from the Fred Hutchinson Cancer Research Center advise that low-dose daily aspirin for prevention of pancreatic cancer may not be for everyone.
Researchers from the University of Basel were able to show that aspirin use and smoking both influence aging processes of the female genome that are connected to colorectal cancer.
People who take low-dose aspirin for more than 10 years might be reducing their risk for pancreatic cancer, a new study suggests.
Aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce heart attack risk: it lowers risk for colon cancer among people with high levels of a specific type of gene.
Regular aspirin use is associated with a reduced risk of colorectal cancer in association with high hydroxyprostaglandin dehydrogenase 15-(nicotinamide adenine dinucleotide) (15-PGDH) expression.
Taking low doses of aspirin, which inhibits platelet function, after a colon cancer diagnosis appears to be associated with better survival if the tumor cells express HLA class I antigen.
A study of almost 20,000 women found the drug lowered ovarian cancer risk by 20 percent.
Aspirin improves outcomes in patients whose tumor cells express a specific protein on their surface that is known as human leukocyte antigen class I (HLA class I), according to research.
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- LIVESTRONG Exercise Program Improves QoL in Cancer Survivors
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
- RANKL Inhibition May Represent Promising Breast Cancer Prevention Strategy
- Bi-allelic Inactivation Common in BRCA1 and BRCA Breast Cancers
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|